Table 2.
Sarcopenia (N = 68) |
Non sarcopenia (N = 104) |
p value | |
---|---|---|---|
Age, mean ± SD | 51.8 ± 12.2 | 51.2 ± 11.3 | 0.729 |
Gender, N (%) | 0.002 | ||
Male | 52(76.5) | 97(93.3) | |
Female | 16(23.5) | 7(6.7) | |
Body mass index (kg/m2), median (IQR) | 20.5(18.3–24.2) | 22.7(21.0–24.2) | 0.002 |
Viral status, N (%) | 0.036 | ||
HCV | 1(1.5) | 2(1.9) | |
HBV | 56(82.3) | 95(91.4) | |
HCV + HBV | 0(0.0) | 2(1.9) | |
None | 11(16.2) | 5(4.8) | |
Alcohol consumption, N (%) | 0.452 | ||
> 80 g per day | 6(8.8) | 13(12.5) | |
Smoking status, N (%) | 0.261 | ||
Never | 45(66.2) | 56(53.9) | |
former | 7(10.3) | 12(11.5) | |
current | 16(23.5) | 36(34.6) | |
BCLC stage, N (%) | 0.392 | ||
B | 12(17.6) | 24(23.1) | |
C | 56(82.4) | 80(76.9) | |
ECOG-PS, N (%) | 0.594 | ||
0 | 33(48.5) | 59(56.7) | |
1 | 29(42.7) | 39(37.5) | |
2 | 4(5.9) | 5(4.8) | |
3 | 2(2.9) | 1(1.0) | |
Child-Pugh Class, N (%) | 0.266 | ||
A | 54(79.4) | 84(80.8) | |
B | 12(17.7) | 20(19.2) | |
C | 2(2.9) | 0(0.0) | |
Comorbidity, N (%) | |||
Hypertension (yes/no) | 17/51(25.0/75.0) | 18/86(17.3/82.7) | 0.221 |
Diabetes (yes/no) | 10/58(14.7/85.3) | 10/94(9.6/90.4) | 0.309 |
Liver Cirrhosis (yes/no) | 33/35(48.5/51.5) | 69/35(66.3/33.7) | 0.020 |
Previous treatment (yes/no), N (%) | 60/8(88.2/11.8) | 94/10(90.4/9.6) | 0.653 |
Baseline metastasis (yes/no), N (%) | 59/9(86.8/13.2) | 76/28(73.1/26.9) | 0.033 |
SD Standard deviation, IQR Interquartile range, HCV Hepatitis s C virus, HBV Hepatitis B virus, BCLC Barcelona Clinic Liver Cancer, ECOG Eastern Cooperative Oncology Group, PS Performance status